Ascletis Pharma Inc. (HKG:1672)
Hong Kong
· Delayed Price · Currency is HKD 16.51
-0.17 (-1.02%)
Apr 29, 2026, 4:08 PM HKT
Ascletis Pharma Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 1,444 | 865.73 | 330.12 | 403.77 | 2,495 | Upgrade
|
| Short-Term Investments | 434.32 | 1,079 | 1,948 | 2,070 | 2.59 | Upgrade
|
| Trading Asset Securities | 26.1 | 7.37 | 24.83 | 11.2 | 5.2 | Upgrade
|
| Cash & Short-Term Investments | 1,904 | 1,953 | 2,303 | 2,485 | 2,503 | Upgrade
|
| Cash Growth | -2.49% | -15.23% | -7.30% | -0.74% | -7.84% | Upgrade
|
| Accounts Receivable | 0.22 | 0.15 | 5.43 | 23.87 | 53.61 | Upgrade
|
| Other Receivables | 9.94 | 9.11 | 12.85 | 5.4 | 13.79 | Upgrade
|
| Receivables | 10.16 | 9.26 | 18.28 | 29.27 | 67.39 | Upgrade
|
| Inventory | 1.87 | 4.37 | 6.07 | 20.52 | 56.23 | Upgrade
|
| Prepaid Expenses | 1.21 | 1.01 | 1.03 | 2.13 | 2.3 | Upgrade
|
| Other Current Assets | 3.54 | 3.62 | 4.13 | 8.13 | 2.34 | Upgrade
|
| Total Current Assets | 1,921 | 1,971 | 2,333 | 2,545 | 2,632 | Upgrade
|
| Property, Plant & Equipment | 46.7 | 57.07 | 68.28 | 71.83 | 77.51 | Upgrade
|
| Long-Term Investments | 88.1 | 84.39 | 63.02 | 22.02 | 41.86 | Upgrade
|
| Other Intangible Assets | 10.29 | 12.12 | 26.32 | 16.56 | 78.21 | Upgrade
|
| Long-Term Deferred Charges | 0.46 | 0.08 | 0.38 | 0.7 | 0.42 | Upgrade
|
| Other Long-Term Assets | 0.26 | 0.13 | 0.26 | 1.22 | 0.41 | Upgrade
|
| Total Assets | 2,067 | 2,125 | 2,491 | 2,657 | 2,830 | Upgrade
|
| Accounts Payable | 1.34 | 0.03 | 0.65 | 3.14 | 1.05 | Upgrade
|
| Accrued Expenses | 87.12 | 83.8 | 91.87 | 56.15 | 52.29 | Upgrade
|
| Current Portion of Leases | 2.87 | 6.25 | 5.71 | 2.42 | 1.57 | Upgrade
|
| Current Unearned Revenue | 1.59 | 1.98 | 1.59 | 1.97 | 1.59 | Upgrade
|
| Other Current Liabilities | 34.67 | 61 | 40.86 | 44.52 | 34.47 | Upgrade
|
| Total Current Liabilities | 127.59 | 153.05 | 140.68 | 108.19 | 90.97 | Upgrade
|
| Long-Term Leases | 2.29 | 1.39 | 2.71 | 1.82 | 1.18 | Upgrade
|
| Long-Term Unearned Revenue | 2.38 | 3.97 | 5.56 | 7.15 | 8.73 | Upgrade
|
| Total Liabilities | 132.26 | 158.41 | 148.94 | 117.16 | 100.89 | Upgrade
|
| Common Stock | 0.68 | 0.69 | 0.73 | 0.74 | 0.75 | Upgrade
|
| Additional Paid-In Capital | - | 2,750 | 2,843 | 2,867 | 2,884 | Upgrade
|
| Retained Earnings | - | -1,475 | -1,174 | -1,030 | -714.85 | Upgrade
|
| Treasury Stock | - | -56.7 | -51.95 | - | -18.71 | Upgrade
|
| Comprehensive Income & Other | 1,934 | 747.55 | 724.56 | 702 | 578.32 | Upgrade
|
| Total Common Equity | 1,934 | 1,966 | 2,342 | 2,540 | 2,729 | Upgrade
|
| Shareholders' Equity | 1,934 | 1,966 | 2,342 | 2,540 | 2,729 | Upgrade
|
| Total Liabilities & Equity | 2,067 | 2,125 | 2,491 | 2,657 | 2,830 | Upgrade
|
| Total Debt | 5.16 | 7.63 | 8.42 | 4.24 | 2.75 | Upgrade
|
| Net Cash (Debt) | 1,899 | 1,945 | 2,295 | 2,480 | 2,501 | Upgrade
|
| Net Cash Growth | -2.37% | -15.25% | -7.48% | -0.80% | -7.89% | Upgrade
|
| Net Cash Per Share | 1.95 | 1.94 | 2.14 | 2.28 | 2.28 | Upgrade
|
| Filing Date Shares Outstanding | 991.87 | 971.07 | 1,061 | 1,087 | 1,096 | Upgrade
|
| Total Common Shares Outstanding | 991.87 | 971.07 | 1,061 | 1,087 | 1,096 | Upgrade
|
| Working Capital | 1,793 | 1,818 | 2,192 | 2,437 | 2,541 | Upgrade
|
| Book Value Per Share | 1.95 | 2.02 | 2.21 | 2.34 | 2.49 | Upgrade
|
| Tangible Book Value | 1,924 | 1,954 | 2,316 | 2,523 | 2,651 | Upgrade
|
| Tangible Book Value Per Share | 1.94 | 2.01 | 2.18 | 2.32 | 2.42 | Upgrade
|
| Machinery | - | 127.38 | 126.13 | 121.54 | 115.33 | Upgrade
|
| Construction In Progress | - | - | - | - | 0.03 | Upgrade
|
| Leasehold Improvements | - | 2.87 | 2.87 | 2.87 | 2.87 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.